Feasibility of evaluating AI-enabled digital symptom monitoring in metastatic patients with NSCLC receiving pembrolizumab therapy: A German single-arm observational pilot study.

ABSTRACT:

Introduction

Close symptom monitoring can benefit patients with metastatic nonsmall cell lung cancer (mNSCLC) receiving first-line therapy. Remote patient monitoring technologies, like the artificial intelligence (AI)-enabled Kaiku^® Health platform that allows oncology patients to report their health status in real-time to healthcare providers, may enhance patients' treatment experience.

Methodology

The lung artificial intelligence-enabled digital solution pilot study ("Lung AID") assessed the feasibility of future studies on Kaiku^® Health in patients with mNSCLC receiving first-line pembrolizumab in Germany. Patient engagement with Kaiku^® Health and practicality of collecting patient-reported outcomes (PROs) via the separate Lung AID EDC sys

SUBMITTER: Santorelli ML 

PROVIDER: S-EPMC12268122 | biostudies-literature | 2025 Jan-Dec

REPOSITORIES: biostudies-literature